Literature DB >> 23810018

Antipsychotics for acute schizophrenia: making choices.

Christoph U Correll1, Marc De Hert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23810018     DOI： 10.1016/S0140-6736(13)61032-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 2.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

Review 3.  The evidence-based choice for antipsychotics in children and adolescents should be guaranteed.

Authors:  Daria Putignano; Antonio Clavenna; Laura Reale; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2019-02-07       Impact factor: 2.953

Review 4.  Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials.

Authors:  A K Pagsberg; S Tarp; D Glintborg; A D Stenstrøm; A Fink-Jensen; C U Correll; R Christensen
Journal:  BMJ Open       Date:  2014-10-10       Impact factor: 2.692

5.  Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.

Authors:  Eric Achtyes; Adam Simmons; Anna Skabeev; Nikki Levy; Ying Jiang; Patricia Marcy; Peter J Weiden
Journal:  BMC Psychiatry       Date:  2018-09-12       Impact factor: 3.630

6.  Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.

Authors:  Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Javier Vázquez-Bourgon; Paula Suárez-Pinilla; Rodrigo Romero-Jiménez; Esther Setién Suero; Rosa Ayesa-Arriola; Benedicto Crespo-Facorro
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-23       Impact factor: 5.176
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.